home.aspx
 
. https://pharmaceutical.report/Resources/Whitepapers/2d50d3b1-20c8-4429-b101-080df2e1c948_Teva Pharma sinks on Q1 revenue miss amid generic competition.pdf
infographic
SHARESHARESHARE
TEVA PHARMA SINKS ON Q1 REVENUE MISS AMID GENERIC COMPETITION
Drugmaker Teva Pharmaceutical (NYSE: TEVA) reported a decline in first-quarter adjusted earnings, owing to a 15% fall in revenues as the company continues to face stiff competition in the generic market. Though earnings surpassed analysts’ forecast, the stock dropped early Thursday. DOWNLOAD